Plain-English translation of NCT07449325 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This early-stage trial is testing a new implanted device called the A-FLUX Coronary Sinus Reducer to help people with microvascular dysfunction—a condition where the heart's smallest blood vessels don't work properly—causing chest pain and shortness of breath. The device is designed to improve blood flow to the heart and relieve symptoms in people who haven't gotten better with medication alone. This is a small, early feasibility study enrolling 30 people to see if the treatment is safe and works as intended.
Many people suffer from chest pain caused by problems in the heart's tiniest blood vessels, even after trying multiple heart medications. This trial exists because there is currently no established device treatment for this condition, and doctors need to test whether this new approach can safely help these patients feel better.
If you qualify, you will undergo a heart catheterization procedure during which the A-FLUX Reducer device is implanted into the coronary sinus (a vein that drains blood from the heart). The procedure involves small tubes passed through blood vessels, similar to other heart catheterization procedures. You will then have follow-up visits to check how you are doing, monitor your symptoms, and ensure the device is working safely. The trial will track how your chest pain symptoms improve and how well the device performs over time.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States